Table 1.

Patient characteristics at first visit during second-year follow-up postdiagnosis

Number of patients	165
Age	57.3 (13.7)*
Female	59%
Rheumatoid factor positive	60%
Disease duration in months	12.5 (11.8–13.2)†
DAS28	3.0 (1.1)*
PROM score	32 (24)*
Receiving DMARD	78% (Methotrexate)‡
Receiving biologic	13% (Adalimumab)‡

*Mean (SD).

†Median (IQR).

‡Most prevalent agent.

DAS₂₈, Disease Activity Score 28-joint count; DMARD, disease-modifying antirheumatic drug; PROM score, patient-reported outcome measure score consisting of an equally weighted mean of visual analogue scales for general health, pain and disease activity.